SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jesspro who wrote (4348)8/3/2016 3:35:24 PM
From: Biomaven  Read Replies (1) of 4474
 
Yes, you might have to fight with the insurer to get coverage. CVS just dropped Tasigna and Xtandi from their formulary - that's pretty dramatic (and horrendous in my opinion).

The key difference between a front line trial and a second line trial is what drugs the patients have previously taken. Front line they need to be "virgins," at least wrt to other TKI's here (might allow some previous chemo).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News